XMRV is Xenotropic murine leukemia virus-related virus. In the past, there were reports that this retrovirus was associated with prostate cancer, but then other reports found no link.
ground-based EMS service after major trauma; a comparison of side effects and mortality after prostate cancer treatment by 1 of 3 forms of radiation (conformal, IMRT, or proton therapy); and, ... This is crucial, I know this from my prior experience in
And just two weeks ago the U.S. Preventive Healthcare Task Force's recommended against PSA screening for prostate cancer. ... Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (National Cancer Institute clinical trial page).
The problem here, as with prostate cancer, is when we find a problem in otherwise healthy people, we may do more harm poking around than if we had just waited for ... The truth is, the fastest way to get heart disease, autism, glaucoma, diabetes,
test to screen for prostate cancer. ... Cancer is the enemy we want to chase down and dispatch before it dispatches us.
Apalutamide (Erleada), the first FDA-approved drug to treat patients with nonmetastatic prostate cancer that continues to grow despite treatment with hormone therapy. ... Tc-99m is a diagnostic agent used with imaging devices to detect potential diseases,
opioids. Docetaxel injection USP (160 mg/8 mL, 20 mg/2 mL single-dose vials; 80 mg/8mL, 160 mg/16 mL multidose vials) to treat patients with breast cancer, ... small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma, squamous
Degarelix, a new injectable drug to treat advanced prostate cancer by suppressing testosterone. ... Imatinib mesylate (Gleevec), to stop cancer from growing after surgical removal of a gastrointestinal stromal tumor.
I've written previously about the limitations and risks of mass screening techniques, e.g., mammography for breast cancer, PSA testing for prostate cancer and PAP smears for cervical cancer. ... The mass screening model, as with mammography or prostate
A safety announcement that an FDA review found no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo). ... The additional studies concluded that entacapone use is not associated with an increased